RESEARCH TRIANGLE PARK, N.C., Dec. 13, 2022 -- Pappas Capital, a global venture capital and commercial development firm, announced today the appointment of Richard Staub as Venture Partner. His appointment...
X-Ceptor focused on the identification of novel drug candidates that interact with orphan nuclear receptors involved in cholesterol metabolism and cardiovascular disease. Several of its programs were partnered and further developed by large pharmaceutical companies.
Exelixis acquired X-Ceptor in 2004.
X-Ceptor Therapeutics
San Diego, CA
© 2023 Pappas Capital, LLC. ALL RIGHTS RESERVED.